Merck KGaA v Merck Sharp Dohme Corp
[2019] FCA 1084
At a glance
Source factsCourt
Federal Court of Australia
Decision date
2019-07-12
Before
Nicholas J
Source
Original judgment source is linked above.
Judgment (10 paragraphs)
Background 1 Before me is an interlocutory application brought by the applicant in the proceeding ("Merck") seeking to have a number of preliminary issues determined separately and before all other issues in the proceeding. 2 The first respondent ("MSD"), the second respondent ("MSD Australia"), and the third respondent ("Intervet Australia"), oppose the determination of any separate question. Each of them submitted that it was not appropriate to consider any of the separate questions proposed by Merck at this stage and that they should be determined at the final hearing together with all other issues in the proceeding. 3 In accordance with orders made on 24 October 2018, the parties have made submissions in relation to the desirability of having the Court determine the proposed separate questions in advance of the final hearing and, in addition, as to how those questions should be answered. This will allow me to answer the separate questions in the event I am satisfied that it is appropriate to do so at this stage of the proceeding. 4 The proposed questions concern the operation of a co-existence agreement comprising two related written agreements. The first is an agreement said by Merck to have been entered into on 1 January 1970 between E Merck (the predecessor of Merck) with MSD (then called Merck & Co Inc) in Darmstadt in Germany ("the 1970 Agreement") and a further agreement said to have been entered into on 24 November 1975 between E Merck (the predecessor of Merck) with MSD (then called Merck & Co Inc) to clarify and augment the 1970 Agreement ("the 1975 Protocol"). The 1970 Agreement and the 1975 Protocol are together referred to as "the Agreement" in the Further Amended Statement of Claim dated 3 December 2018 ("FASOC"). 5 The 1970 Agreement replaced an earlier agreement ("the 1955 Agreement") which had been signed on or about 12 September 1955. The 1970 Agreement and the 1955 Agreement are substantially identical in their terms. Clause 12 of the 1970 Agreement stated that it "… provides for formalistic amendments caused by a change of the company name of the German party." 6 Merck is a company incorporated in 1995 under the laws of Germany. It is the successor to the title, business rights and obligations of earlier German partnerships known as various "E. Merck KG or E. Merck ("E. Merck"). 7 MSD Australia was incorporated in Australia in April 1956. Between 1956 and November 2009 MSD was the ultimate holding company for MSD Australia. Since November 2009 the company now known as Merck & Co Inc ("Merck & Co") has been the ultimate holding company of MSD Australia. Intervet Australia was incorporated in December 1968. Since about November 2009 Merck & Co has been the ultimate holding company for Intervet Australia. Both MSD Australia and Intervet Australia are wholly owned subsidiaries of MSD. In these reasons I shall refer to them collectively as the "MSD subsidiaries". 8 Merck alleges that MSD has breached the Agreement by permitting MSD Australia and Intervet Australia to use in Australia the word "Merck" in breach of the Corporate Name Term. Merck is also alleged to have breached the Agreement by permitting those companies to use in Australia the word "Merck" as a trade mark. 9 Merck also alleges that MSD, MSD Australia and Intervet Australia have infringed various Australian registered trade marks owned by Merck. 10 There is an issue between the parties as to which law governs the 1970 Agreement. There is also an issue between the parties as to whether or not the 1970 Agreement contains a particular contractual term referred to in para 11 of the FASOC as the "Corporate Name Term". 11 Merck contends that the 1970 Agreement is governed by the law of the Federal Republic of Germany ("German Law") whereas MSD contends that it is governed by the laws of New Jersey ("New Jersey Law"). 12 Merck and MSD have been engaged in litigation in a number of jurisdictions in relation to the 1970 Agreement and the 1975 Protocol. This litigation has given rise to a number of decisions in overseas jurisdictions including the following three UK judgments in proceedings commenced by Merck against MSD, Merck & Co and three European subsidiaries ("the UK proceedings"): the judgment of the High Court of Justice of England and Wales in Merck KGaA v Merck Sharp & Dohme Corp [2014] EWHC 3867 (Ch) ("UK Governing Law Decision"); the judgment of the High Court of Justice of England and Wales in Merck KGaA v Merck Sharp & Dohme [2016] EWHC 49 (Pat) ("UK Trial Judgment"); and the judgment of the Court of Appeal of England and Wales in Merck KGaA v Merck Sharp & Dohme [2017] EWCA Civ 1834 ("UK Appeal Judgment"). It is common ground that neither of the MSD subsidiaries (ie. the second and third respondents to this proceeding) was a party to the UK proceedings. 13 The questions postulated by Merck for separate determination are as follows: (1) Is MSD precluded from denying that the 1970 Agreement and the 1975 Protocol (as defined in paragraphs 7 and 9 of the FASOC) are governed by the law of the Federal Republic of Germany by reason of: (a) estoppel; and/or (b) abuse of process of this Court, based on the judgments of the English Court in the UK Governing Law Decision, the UK Appeal Judgment and the UK Trial Judgment ("the Governing Law Question")? (2) Is MSD precluded from denying that the Corporate Name Term (as defined in paragraph 11 (a) of the FASOC) was a term of the Agreement (as defined in paragraph 10 of the FASOC) by reason of: (a) estoppel; and/or (b) abuse of process of this Court, based on the UK Trial Judgment and the UK Appeal Judgment ("the Corporate Name Term Question")? 14 The paragraphs of the FASOC referred to in the relevant questions relevantly allege: 7. On 1 January 1970, E. Merck (the predecessor of Merck) entered into an agreement with MSD (then called Merck & Co., Inc.) in Darmstadt in Germany (1970 Agreement). … 9. On 24 November 1975, E. Merck (the predecessor of Merck) entered into an agreement with MSD (then called Merck & Co., Inc.) to clarify and augment the 1970 Agreement (1975 Protocol). … 11. In accordance with the principles of German law as to the proper construction of the Agreement, the Agreement relevantly prohibited MSD from: (a) itself, and its subsidiaries and affiliates (as defined in the 1970 Agreement), using in Australia the word "Merck" on its own as, or as part of, its corporate, company, firm, trade or business name, or as a contraction thereof, otherwise than as expressly permitted under the Agreement (the Corporate Name Term); and … 15 Paragraph 11 of the FASOC also alleges in subpara (b), that the Agreement prohibited MSD and its subsidiaries and affiliates (as defined in the 1970 Agreement), from using in Australia the word "Merck" as a trade mark. The respondents deny that the Agreement contained this additional term ("the Trade Mark Term") although it is not picked up in the separate questions propounded by Merck. The respondents point out, correctly in my view, that the question whether the Agreement contains the Trade Mark Term is an issue that will need to be determined at the trial regardless of how the proposed separate questions are answered. If the Agreement is governed by German law (as Merck contends) then that question will most likely need to be resolved in the light of expert evidence in relation to German law. 16 Paragraph 12 of the FASOC alleges: Under German law, each of MSD Australia and Intervet is a subsidiary or affiliate of or under the control of MSD, within the meaning of clause 1 of the 1970 Agreement, and accordingly MSD is liable for any conduct of MSD Australia or Intervet which would, if those entities were parties to the Agreement, constitute a breach of the Agreement. 17 In their defence the respondents admit that MSD entered into the 1970 Agreement, though they deny that the 1970 Agreement was entered into in Darmstadt in Germany. They assert that the 1970 Agreement is governed by the law of New Jersey and that the law of that jurisdiction is the proper law of the Agreement. 18 It is not suggested by any party that the MSD subsidiaries are parties to the Agreement or that they could be liable to Merck in this proceeding for breach of contract. Mr Lancaster SC, who appeared for Merck, made clear in his submissions that to the extent there may be any ambiguity in Merck's pleading, Merck would amend to eliminate any conceivable ambiguity. This has now been done by the filing of the FASOC. 19 For the reasons that follow I am satisfied that it is appropriate to determine the Governing Law Question separately and before all other issues in the proceeding and that it should be answered affirmatively. I do not propose to consider the Corporate Name Term Question as a separate question. Rather, I think the most appropriate course is to determine that question along with all other issues that remain to be determined at the final hearing.